PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer
Science Translational Medicine · 2025
DOI: 10.1126/scitranslmed.adr3718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2025. Verfasst von Irene Fusi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, University Hospital Basel and University of Basel, 4031 Basel, Switzerland. Hauptthemen laut MEDLINE: Interleukin-2, Programmed Cell Death 1 Receptor, Lung Neoplasms, T-Lymphocytes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Antibody-cytokine fusion proteins are being developed as next-generation cancer immunotherapies, aiming to deliver activation signals to targeted immune populations. Among these, PD1-IL2v—an engineered interleukin-2 variant (IL-2v) lacking CD25 binding, fused to a high-affinity programmed cell death protein 1 (PD-1) blocking antibody—has shown promising results in murine tumor models. Here, using human model systems, we show that PD1-IL2v elicits a multifaceted antitumor T cell response by targeting both CD8 + and conventional CD4 + T (T conv ) cells. Single-cell RNA sequencing (scRNAseq) on a lung cancer patient–derived tumor fragment (PDTF) platform revealed that PD1-IL2v drives the expansion of proliferative, cytotoxic CD8 + T cells exhibiting features of tumor reactivity. This was accompanied by up-regulation of CXCR6, enhancing their migratory capacity. In T conv cells, PD1-IL2v up-regulated CXCL13 expression and promoted a T follicular helper/T helper 1 (T FH /T H 1)–like transcriptional program associated with anti-PD1 responsiveness. Our findings provide mechanistic insights into the effects of IL-2v–targeted delivery to PD-1 + cells within human tumors, supporting the clinical development of next-generation immunocytokines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.
- Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
- Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.
- Institute of Medical Genetics and Pathology, University Hospital Basel, 4031 Basel, Switzerland.
- Department of Thoracic Surgery, University Hospital Basel, 4031 Basel, Switzerland.
- Roche Pharma Research and Early Development, Early Development Oncology Biomarkers, Roche Innovation Center Basel, 4070 Basel, Switzerland.
ORCID-Profile: Irene Fusi, Clara Serger, Markus Germann, Michael T Sandholzer, Nicole Oelgarth, Petra C Schwalie, Viola K Vetter, Viktor H Koelzer, Henry Kao, Laura Codarri Deak, Pablo Umaña, Christian Klein, Aljaz Hojski, Marina Natoli, Alfred Zippelius
Zitieren
APA
Fusi, I., Serger, C., Herzig, P., Germann, M., Sandholzer, M. T., Oelgarth, N., Schwalie, P. C., Don, L., Vetter, V. K., Koelzer, V. H., Lardinois, D., Kao, H., Deak, L. C., Umaña, P., Klein, C., Hojski, A., Natoli, M., & Zippelius, A. (2025). PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adr3718
Vancouver
Fusi I, Serger C, Herzig P, Germann M, Sandholzer MT, Oelgarth N, et al. PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer. Science Translational Medicine. 2025. doi:10.1126/scitranslmed.adr3718
BibTeX
@article{Fusi2025,
author = {Fusi, Irene and Serger, Clara and Herzig, Petra and Germann, Markus and Sandholzer, Michael T and Oelgarth, Nicole and Schwalie, Petra C and Don, Leyla and Vetter, Viola K and Koelzer, Viktor H and Lardinois, Didier and Kao, Henry and Deak, Laura Codarri and Umaña, Pablo and Klein, Christian and Hojski, Aljaz and Natoli, Marina and Zippelius, Alfred},
title = {PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer},
journal = {Science Translational Medicine},
year = {2025},
doi = {10.1126/scitranslmed.adr3718}
}
EUVIMED